reports
Advanced Proteome Therapeutics Reports Positive Results and Advances C...
Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma VANCOUVER, British Columbia , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC's proprietary site-selective pro...
Advanced Proteome Therapeutics Reports Progress on Collaboration with ...
Advanced Proteome Therapeutics Reports Progress on Collaboration with Noria Pharmaceuticals VANCOUVER, British Columbia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the successful completion of the first phase of the Collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing and dynamic field of antibody radioisotope conjugates which is expected to have a major impact in the fight against cancer. APC has succeeded in creating a construct using its proprietary, site-se...
APC Comments on Favorable Results in Initial Animal Studies
APC Comments on Favorable Results in Initial Animal Studies VANCOUVER, British Columbia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report favorable results in initial animal studies. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens. The combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroo...
Advanced Proteome Therapeutics Announces Progress on Antibody-Radioiso...
Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates. APC has initiated a program to create well-defined, chemically controlled constructs that are expected to display higher selectivity and efficiency than has previously...
Advanced Proteome Therapeutics Provides Overview of Current Activities...
Advanced Proteome Therapeutics Provides Overview of Current Activities and Strategic Objectives VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to provide an overview of current projects prior to more detailed news releases that will be disclosed shortly. Radioimmunoconjugates APC’s site-selective technology is being employed in the emergent field of radioimmunoconjugates (radioactive substances that can carry radiation directly to cancer cells.) These conjugates are ma...
Advanced Proteome Therapeutics Announces Closing of First Tranche of a...
Advanced Proteome Therapeutics Announces Closing of First Tranche of a Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that it has closed a first tranche of a non-brokered private placement (the “Private Placement”) raising gross proceeds of $302,000 by the issuance of 6,040,000 units at a price of $0.05 per Unit. Each unit consists of o...
Advanced Proteome Therapeutics Announces Non-Brokered Private Placemen...
Advanced Proteome Therapeutics Announces Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, subject to the approval of the TSX Venture Exchange (the “Exchange”), it proposes to raise up to $400,000 through a non‑brokered private placement of up to 8,000,000 units at a price of $0.05 per unit. Each unit will consist of one common share and...
Advanced Proteome Therapeutics Announces Collaboration with Noria Phar...
Advanced Proteome Therapeutics Announces Collaboration with Noria Pharmaceuticals VANCOUVER, British Columbia, July 17, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to announce the collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing field of antibody radioisotope conjugates. APC will test its proprietary, site-selective, linker technology with Noria’s proprietary MacroPA radioisotope chelation technology in combination with antibodies known to preferentially target cancer cells. The s...
Advanced Proteome Therapeutics Advances its Technological Capability
Advanced Proteome Therapeutics Advances its Technological Capability VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs). Proceeding from cytotoxicity studies to the next phase of testing in animals necessitates scaling up processes by a significant factor that often requires outsourcing to other companies at considerable cost and down time. APC can now report that it has achieved...
Advanced Proteome Therapeutics Announces Appointment of Bill Dickie as...
Advanced Proteome Therapeutics Announces Appointment of Bill Dickie as Chief Executive Officer, President and Director VANCOUVER, British Columbia, June 06, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointment of Mr. Bill Dickie as Chief Executive Officer, President and Director of the company, effective June 6, 2018. Mr. Dickie brings with him more than 30 years of exceptionally qualified experience in business leadership, development and execution of growth strategies within the healthcar...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.